MONTREAL, QUEBEC--(Marketwire - Aug. 3, 2012) -
THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.
Osta Biotechnologies Inc. (the "Corporation") (TSX VENTURE:OBI) announces that the TSX Venture Exchange (the "Exchange") has transferred its listing to the NEX board of the Exchange (the "NEX") effective as of the opening of trading on Friday, August 3, 2012. The Corporation's share symbol will remain OBI and the common shares will remain suspended.
The Corporation continues to review and consider several business opportunities and its transfer to the NEX will not materially impact this strategy.
Osta Biotechnologies Inc.
Osta is a biopharmaceutical company listed on the TSX Venture Exchange (TSX VENTURE:OBI) currently focusing on developing therapeutics for Cancer and Alzheimer's disease.
Certain information in this press release is forward-looking and is subject to numerous risks and uncertainties. By their nature, such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include actions of Osta's competitors, and those inherent in scientific research and development.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.